Dept. of Chemical Engineering and Chemical Technology, Imperial College London, South Kensington Campus, London, UK.
Biotechnol Prog. 2011 Nov-Dec;27(6):1730-43. doi: 10.1002/btpr.688. Epub 2011 Sep 28.
Monoclonal antibodies (mAbs) are one of the most important products of the biopharmaceutical industry. Their therapeutic efficacy depends on the post-translational process of glycosylation, which is influenced by manufacturing process conditions. Herein, we present a dynamic mathematical model for mAb glycosylation that considers cisternal maturation by approximating the Golgi apparatus to a plug flow reactor and by including recycling of Golgi-resident proteins (glycosylation enzymes and transport proteins [TPs]). The glycosylation reaction rate expressions were derived based on the reported kinetic mechanisms for each enzyme, and transport of nucleotide sugar donors [NSDs] from the cytosol to the Golgi lumen was modeled to serve as a link between glycosylation and cellular metabolism. Optimization-based methodologies were developed for estimating unknown enzyme and TP concentration profile parameters. The resulting model is capable of reproducing glycosylation profiles of commercial mAbs. It can further reproduce the effect gene silencing of the FucT glycosylation enzyme and cytosolic NSD depletion have on the mAb oligosaccharide profile. All novel elements of our model are based on biological evidence and generate more accurate results than previous reports. We therefore believe that the improvements contribute to a more detailed representation of the N-linked glycosylation process. The overall results show the potential of our model toward evaluating cell engineering strategies that yield desired glycosylation profiles. Additionally, when coupled to cellular metabolism, this model could be used to assess the effect of process conditions on glycosylation and aid in the design, control, and optimization of biopharmaceutical manufacturing processes.
单克隆抗体 (mAbs) 是生物制药行业最重要的产品之一。它们的治疗效果取决于糖基化的翻译后过程,而这一过程受到制造工艺条件的影响。在此,我们提出了一个 mAb 糖基化的动态数学模型,通过将高尔基体近似为推流反应器并包括高尔基体驻留蛋白(糖基化酶和转运蛋白 [TP])的再循环来考虑内质网成熟。糖基化反应速率表达式是根据每个酶的报告动力学机制推导出来的,并且从细胞质到高尔基体腔的核苷酸糖供体 [NSD] 的运输被建模为糖基化和细胞代谢之间的联系。开发了基于优化的方法来估计未知的酶和 TP 浓度分布参数。所得模型能够再现商业 mAb 的糖基化谱。它还可以再现 FucT 糖基化酶基因沉默和细胞质 NSD 耗竭对 mAb 寡糖谱的影响。我们模型的所有新元素都基于生物学证据,并且比以前的报告产生更准确的结果。因此,我们认为这些改进有助于更详细地表示 N-连接糖基化过程。总体结果表明,该模型有潜力评估产生所需糖基化谱的细胞工程策略。此外,当与细胞代谢耦合时,该模型可用于评估工艺条件对糖基化的影响,并有助于生物制药制造工艺的设计、控制和优化。